Related Experiment Video
Updated: May 2, 2026
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Targeting tumour-supportive cellular machineries in anticancer drug development
Matthias Dobbelstein1, Ute Moll2
1Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences, Ernst Caspari Haus, University Medical Center Göttingen, 37077 Göttingen, Germany.
Abstract:
Traditional anticancer chemotherapeutics targeting DNA replication and cell division have severe side effects, but they have proved to be highly successful in treating some cancers. Drugs targeting signalling oncoproteins that have gained tumour-driving functions through mutations or overexpression were subsequently developed to increase specificity and thus reduce side effects, but have limitations such as the development of resistance. Now, a new wave of small-molecule anticancer agents is emerging, targeting complex multicomponent cellular machineries - including chromatin modifiers, heat shock protein chaperones and the proteasome - which thus interfere with those support systems that are more essential for cancer cells than for normal cells. Here, we provide our perspective on the advantages and limitations of agents that target tumour-supportive cellular machineries (other than those involving DNA replication), comparing them with agents that target signalling intermediates.
Insights
New anticancer drugs target cancer cell support systems, offering a promising alternative to traditional chemotherapy and targeted therapies. These novel agents show potential for improved efficacy and reduced side effects in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Traditional chemotherapy and targeted therapies have limitations, including severe side effects and drug resistance.
- Novel anticancer strategies are needed to improve treatment outcomes and patient quality of life.
Purpose of the Study:
- To provide a perspective on emerging small-molecule anticancer agents.
- To discuss the advantages and limitations of targeting tumor-supportive cellular machineries.
- To compare these novel agents with those targeting signaling intermediates.
Main Methods:
- Review and analysis of current research on novel anticancer agents.
- Comparative assessment of different therapeutic strategies in oncology.
- Discussion of the mechanisms of action for agents targeting cellular machineries.
Main Results:
- Emerging small-molecule agents target complex cellular machineries essential for cancer cell survival.
- These targets include chromatin modifiers, heat shock protein chaperones, and the proteasome.
- Targeting these machineries offers a potential strategy to overcome resistance and reduce side effects.
Conclusions:
- Agents targeting tumor-supportive cellular machineries represent a promising new wave in cancer therapy.
- These approaches may offer improved specificity and reduced toxicity compared to traditional methods.
- Further research is warranted to fully explore the potential of these novel anticancer agents.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
01:27Tumor Immunotherapy